Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
Saved in:
| Title: | Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease. |
|---|---|
| Authors: | Feelders RA; Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands., Fleseriu M; Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR, United States., Kadioglu P; Division of Endocrinology, Metabolism and Diabetes, Cerrahpasa Medical Faculty, Istanbul University - Cerrahpasa, Istanbul, Türkiye., Bex M; Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium., González-Devia D; Departamento de Medicina Interna, Sección de Endocrinologia, Hospital Universitario Fundación Santa Fé de Bogotá, Bogota, Colombia., Boguszewski CL; Department of Internal Medicine, Endocrine Division (SEMPR), Federal University of Paraná, Curitiba, Parana, Brazil., Yavuz DG; Section of Endocrinology and Metabolism, Marmara University School of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul, Türkiye., Patino H; Global Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States., Pedroncelli AM; Recordati AG, Basel, Switzerland.; Global Medical Affairs, Novartis Pharma AG, Basel, Switzerland., Maamari R; Global Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States., Chattopadhyay A; Global Medical Affairs, Novartis Healthcare Private Limited, Hyderabad, Telangana, India., Biller BMK; Neuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, United States., Pivonello R; Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy. |
| Source: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Oct 09; Vol. 14, pp. 1165681. Date of Electronic Publication: 2023 Oct 09 (Print Publication: 2023). |
| Publication Type: | Clinical Trial, Phase II; Multicenter Study; Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
